CD22 and diffuse large B-cell lymphoma: These results indicate that CD19/CD22 dual-targeted CAR-T therapy with a decitabine-based regimen shows preliminary efficacy in R/R DLBCL; however, in the absence of a control group, with significant hematologic and systemic toxicities and limited follow-up, its efficacy and safety must be validated in larger randomized trials.